Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11121-11132

  Zhuang, Peng Yuan ^a   Wang, Jian Dong ^a   Tang, Zhao Hui ^a   Zhou, Xue Ping ^a   Yang, Yong ^a   Quan, Zhi Wei ^a   Liu, Ying Bin ^a   Shen, Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Neuropilin 1; Overall survival; Peritumoral tissue; Recurrence; Vascular endothelial growth factor receptor 2

Indexed keywords

NEUROPILIN 1; VASCULOTROPIN RECEPTOR 2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CAPILLARY DENSITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; DISEASE FREE SURVIVAL; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TUMOR RECURRENCE; VASCULARIZATION; XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; PROGNOSIS; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84917690505     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2553     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. 2002. CA Cancer J Clin. 2005; 55:74-108.
3. Liu L, Liu Y, Liu J, Zhai X, Wen J, Xie K, Shen H, Hu Z, Fan Z. Genetic variants in pseudogene E2F3P1 confer risk for HBV-related hepatocellular carcinoma in a Chinese population. J Biomed Res. 2013; 27:215-219.
4. Abou-Alfa GK. American Society of Clinical Oncology Educational Handbook. (Alexandria, Va, USA: American Society of Clinical Oncology 2004) Current and novel therapeutics for hepatocellular carcinoma. 2004; 192-197
5. Kishi Y, Hasegawa K, Sugawara Y, Kokudo N. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol. 2011; 728103.
6. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies J Hepatol. 2012; 56:267-275.
7. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell. 1997; 90: 739-751.
8. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Gigers RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell. 1997; 90:753-762.
9. Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res. 2008; 68: 4683-4692.
10. Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother. 2014; 63:81-99.
11. Berge M, Allanic D, Bonnin P, MontrionC de, Richard J, Suc M. Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling. J Hepatol. 2011; 55:866-875.
12. Patel SH, Kneuertz PJ, Delgado M, Kooby DA, Staley CA 3rd, El-Rayes BF, Kauh JS, Sarmiento JM, Hanish S, Cohen C, Farris AB 3rd, Maithel SK. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. Ann Surg Oncol. 2011; 18:3384-3390.
13. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23:1011-1027.
14. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 2003; 10:355-362.
15. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998; 28:68-77.
16. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T, Nagasue N. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998; 27:1554-1562.
17. Yu D, Zhuang L, Sun X, Chen J, Yao Y, Meng K, Ding Y. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer. 2007; 7:122.
18. Yu GR, Kim SH, Park SH, Cui XD, Xu DY, Yu HC, Cho BH, Yeom YI, Kim SS, Kim SB, Chu IS, Kim DG. Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med. 2007; 39:641-652.
19. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10:99-111.
20. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun K. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92:735-745.
21. Vanveldhuizen PJ, Zulfiqar M, Banerjee S, Cherian R, Saxena NK, Rabe A, Thrasher JB, Banerjee SK. Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue. Oncol Rep. 2003; 10:1067-1071.
22. Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N, Bruns CJ, Bucana CD, Evans DB, Ellis LM. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer. 2003; 98:720-729.
23. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991; 13:372-374.
24. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000; 31:241-246.
25. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10:7252-7259.
26. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology. 2000; 32:43-48.
27. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006; 132:458-465.
28. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003; 9:416-423.
29. Liao C, Zhao M, Song H, Uchida K, Yokoyama KK, Li T. Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology. 2000; 32:721-727.
30. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 89:500-507.
31. Cheng W, Fu D, Wei ZF, Xu F, Xu XF, Liu YH, Ge JP, Tian F, Han CH, Zhang ZY, Zhou LM. NRP-1 expression in bladder cancer and its implications for tumor progression. Tumour Biol. 2014; 35:6089-6094.
32. Younan S, Elhoseiny S, Hammam A, Gawdat R, El-Wakil M, Fawzy M. Role of neuropilin-1 and its expression in Egyptian acute myeloid and acute lymphoid leukemia patients. Leuk Res. 2012; 36:169-173.
33. Yang SL, Liu LP, Jiang JX, Xiong ZF, He QJ, Wu C. The correlation of expression levels of HIF-1alpha and HIF-2alpha in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients' clinical outcome. Jpn J Clin Oncol. 2014; 44:159-167.
34. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, Katsuyama Y, Melillo G, Konishi I. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol. 2007; 38:1310-1320.